Publications by authors named "Tierra Ouellette"
Treatment of tuberculosis (TB) currently takes at least 6 months. Latent (Mtb) is phenotypically tolerant to most anti-TB drugs. A key hypothesis is that drugs that kill nonreplicating (NR) Mtb may shorten treatment when used in combination with conventional drugs.
View Article and Find Full Text PDFArticle Synopsis
- Proteasomes in pathogenic microbes, especially Mycobacterium tuberculosis (Mtb), are being explored as viable targets for new anti-infective drugs due to their ability to help the bacteria resist host defenses.
- Research shows that inhibiting or deleting the Mtb proteasome makes the bacteria more vulnerable to reactive nitrogen species and decreases their survival in host lungs, indicating its potential as a target for anti-Mtb therapies.
- A study developed potent phenylimidazole-based compounds that selectively inhibit Mtb20S by using structure-guided techniques, with X-ray analyses revealing how these compounds specifically interact with mycobacterial proteasomes compared to human ones.
The proteasome (Pf20S) emerged as a target for antimalarials. Pf20S inhibitors are active at multiple stages of the parasite life cycle and synergize with artemisinins, suggesting that Pf20S inhibitors have potential to be prophylactic, therapeutic, and transmission blocking as well as are useful for combination therapy. We recently reported asparagine ethylenediamines (AsnEDAs) as immunoproteasome inhibitors and modified AsnEDAs as selective Pf20S inhibitors.
View Article and Find Full Text PDF